Related by context. All words. (Click for frequent words.) 66 Combination Therapy 65 Neoadjuvant 65 Irinotecan 65 Prolongs Survival 65 Adjuvant Therapy 65 Clinical Outcome 65 Disease Progression 65 Adjuvant Chemotherapy 65 Aliskiren 65 Autologous Stem Cell Transplantation 65 HER2 Positive Breast Cancer 65 bevacizumab Avastin 65 Gastric Cancer 65 Antitumor Activity 64 Anti Tumor Activity 64 Patients Treated 64 Monotherapy 64 Fluorouracil 64 Placebo Controlled Trial 64 Anthracycline 64 Nilotinib 64 Randomized Study 64 Improves Survival 64 Improves Outcomes 64 Improved Survival 64 Adjuvant Treatment 64 Interferon Alpha 64 Sipuleucel T 64 Survival Benefit 64 Clinical Trial Results 63 Anti Tumor 63 Virologic 63 Anticancer Activity 63 Prophylaxis 63 Treatment Naive Patients 63 Pertuzumab 63 Erlotinib 63 Localized Prostate Cancer 63 Kinase Inhibitors 63 Lymphoid 63 JAK Inhibitor 63 Phase III Trial 63 Renal Cell Carcinoma 63 Viral Suppression 63 Hepatocellular Carcinoma 63 mycophenolate mofetil 63 Recombinant Human 63 Anti Angiogenic 63 Immunotherapeutic 63 Meta Analysis 63 Cellular Immunotherapy 63 Bivalirudin 63 Hepatitis C Virus 63 Rheumatoid Arthritis Patients 63 Taxotere ® 63 Gemcitabine 63 Combination Treatment 63 Confirms Efficacy 63 Protease Inhibitor 63 Bladder Cancer 63 Advanced Prostate Cancer 63 Analytical Tool 62 Radiofrequency Ablation RFA 62 Previously Untreated 62 Risk Stratification 62 Unfractionated Heparin 62 Cyclophosphamide 62 Bosutinib 62 Cardiovascular Events 62 Capecitabine 62 Sorafenib 62 Lenalidomide 62 Bevacizumab 62 Statistically Significant 62 Cardiotoxicity 62 Anticancer Drug 62 Metastatic Renal Cell Carcinoma 62 Breast Tumors 62 Low Dose 62 Estrogen Receptor 62 Embolization 62 Phase III Clinical Trial 62 NSABP B 62 Atopic Dermatitis 62 Patients Treated With 62 Severe Sepsis 62 Fulvestrant 62 Intravesical 62 Xelox 62 Pneumococcal Vaccine 62 Immunomodulatory 62 Taxane 62 Orally Active 62 Pemetrexed 62 Chronic Hepatitis C 62 Interferon Beta 62 Chemoradiation 62 Radiofrequency Ablation 62 Allogeneic 62 Tacrolimus 62 Study Evaluating 62 Antiangiogenic 62 Antiviral Activity 62 Breast Cancer Cells 62 Epratuzumab 61 Tumor Targeting 61 Therapeutic Efficacy 61 Targeted Therapy 61 Clinical Efficacy 61 Skeletal Muscle 61 Regimens 61 Demonstrates Efficacy 61 Cytotoxicity 61 Pooled Analysis 61 Liposomal 61 Advanced Melanoma 61 Antitumor 61 Fondaparinux 61 Peginterferon 61 Radical Prostatectomy 61 Investigational Agent 61 Transdermal Delivery 61 Unresectable 61 Tiotropium 61 Trastuzumab 61 Systemic Delivery 61 sorafenib Nexavar 61 Infected Patients 61 Patients Receiving 61 Epidermal Growth Factor Receptor 61 Metastatic Colorectal Cancer 61 Platinol ® 61 Renal Cancer 61 Metastatic Prostate Cancer 61 Degarelix 61 Well Tolerated 61 Hsp# Inhibitor 61 Postmenopausal Women 61 Investigational Drug 61 Daptomycin 61 Preclinical Study 61 Solid Tumors 61 Anticoagulation 61 Therapeutic Antibody 61 Shows Efficacy 61 Previously Treated 61 docetaxel Taxotere ® 61 cinacalcet 61 Bioavailability 61 Prospective Randomized 61 ritonavir boosted 61 Oxaliplatin 60 Dasatinib 60 Novel Oral 60 Phase 2b Clinical Trial 60 Neoadjuvant Chemotherapy 60 Interferon Alfa 60 Immunogenic 60 Parathyroid Hormone 60 Complicated Skin 60 Progressive Multifocal Leukoencephalopathy 60 Soft Tissue Sarcoma 60 Tyrosine Kinase Inhibitor 60 Multicenter Study 60 Pivotal Study 60 Investigational Compound 60 Immunosuppressant 60 Oral Mucositis 60 thalidomide Thalomid 60 Diabetic Foot Ulcer 60 Paraplatin ® 60 Pulmonary Arterial Hypertension 60 Pivotal Trial 60 Blinatumomab 60 Treating Chronic 60 Oral Fingolimod 60 Tolerability 60 Long Term Efficacy 60 Fludarabine 60 Efficacy Trial 60 Appears Safe 60 Deforolimus 60 Monoclonal Antibody 60 Cannabinoid 60 Antifungal 60 Azacitidine 60 Adjuvant Breast Cancer 60 Dendritic Cells 60 erlotinib Tarceva ® 60 Protease Inhibitors 60 Hypercholesterolemia 60 bevacizumab Avastin ® 60 Hormone Refractory Prostate Cancer 60 Carboplatin 60 Bendamustine 60 Immunotherapies 60 Subgroup Analysis 60 Oncolytic 60 Small Molecule 60 Benign Prostatic Hyperplasia 60 Phase 2b Study 60 Acute Ischemic Stroke 60 Breast Cancer Recurrence 60 Breast Cancer Patients 60 paclitaxel Taxol 60 fosbretabulin 60 Shows Promise Against 60 Gemzar ® 60 5 Fluorouracil 60 Vitro Activity 60 Synthetic Peptide 60 Tesamorelin 60 MGd 60 Sustained Efficacy 60 Adverse Event 60 HER2 Positive 60 Single Dose 60 Pegylated 60 Rheumatoid Arthritis Drug 60 Demonstrates Significant 60 Mantle Cell Lymphoma 60 Pandemic Influenza Vaccine 60 Telbivudine 60 Metastatic 60 Cervical Dysplasia 60 Chemotherapeutic Agents 60 Estrogen Therapy 60 Advanced Colorectal Cancer 60 Chronic Hepatitis B 60 Pegylated Interferon 60 Patients Undergoing 60 depsipeptide 60 Pediatric Patients 60 Virus Infection 60 Denufosol 60 Fluticasone 60 Metastatic Disease 60 Universal Flu Vaccine 60 Pharmacokinetic Study 60 Potent Inhibitor 60 Enzyme Replacement Therapy 60 Abatacept 60 alpha 2a 59 Immunogenicity 59 Vaccine Adjuvant 59 Newly Diagnosed Multiple Myeloma 59 Melphalan 59 trabectedin 59 Angiogenic 59 Improve Survival 59 Clostridium difficile Infection 59 Safinamide 59 Polymerase Inhibitor 59 Prostate Biopsy 59 Hemodialysis Patients 59 Meets Primary Endpoint 59 Postmenopausal Osteoporosis 59 Brain Metastases 59 Shows Promising 59 Immunosuppression 59 Prostate Cancer Treatment 59 Radioimmunotherapy 59 Tipranavir 59 Colorectal Cancer Patients 59 Prospective Randomized Trial 59 Thrombotic 59 Glufosfamide 59 pegylated liposomal doxorubicin 59 radiofrequency ablation RFA 59 Lung Cancer Drug 59 Nitazoxanide 59 Breast Cancer Treatment 59 Nymox NX 59 Anti TNF 59 Cutaneous T 59 Chemoprevention 59 Aurora Kinase 59 Cethromycin 59 Statin Therapy 59 Chronic Lymphocytic Leukemia 59 Advanced Renal Cell 59 adalimumab Humira 59 Recurrent Breast Cancer 59 Hepatitis C Infection 59 Cardiovascular Outcomes 59 Anti CD# Antibody 59 Myelodysplastic Syndromes 59 Metastatic Melanoma 59 YONDELIS 59 Breast Cancer Metastasis 59 Neulasta ® 59 See CLINICAL PHARMACOLOGY 59 Antihypertensive 59 fulvestrant 59 Fludara ® 59 Malignancies 59 Preclinical Models 59 PEGylated interferon beta 1a 59 APTIVUS 59 Cytotoxic 59 Carcinoma 59 Acute Coronary Syndromes 59 efavirenz EFV 59 Sirolimus Eluting Stent 59 Ranolazine 59 Multicenter Randomized 59 intratumoral injection 59 Posaconazole 59 Presents Preclinical Data 59 flavopiridol 59 Multicenter Phase 59 Blood Pressure Lowering 59 Dose Escalation Study 59 GW# [003] 59 Pharmacokinetic 59 Relapsed Refractory 59 Drug Candidate 59 Valopicitabine NM# 59 Cell Lymphoma 59 RNAi Therapeutics 59 Immunosuppressive 59 Receives Orphan Drug Designation 59 Double Blind Randomized 59 Genital Herpes 59 Renal Cell Cancer 59 Preclinical Data 59 Infliximab 59 Bortezomib 59 Chemotherapy Regimen 59 Trabectedin 59 adjuvant radiotherapy 59 Initiate Clinical Trial 59 Diabetic Neuropathy 59 Venous Thromboembolism 59 Dapagliflozin 59 Methotrexate 59 Knee Osteoarthritis 59 Erythropoietic 59 Fracture Risk 59 Controlled Trial 59 Apoptotic 59 Immunotherapy 59 Lung Cancer Patients 59 SUTENT ® 59 Cilostazol 59 Eculizumab 59 Therapeutic Vaccine 59 Novel Therapeutic 59 Quantitation 59 amifostine 59 Cetuximab 59 Phase IIb Clinical Trial 59 Carotid Stenting 59 Invasive Breast Cancer 59 metastatic malignant 59 Ibritumomab Tiuxetan 59 Cyclosporine 59 Cytochrome P# 59 Fluconazole 59 Treatment Regimen 59 Tumor Growth 59 Bone Metastases 59 Rectal Cancer 59 Osteoporosis Drug 59 Viral Load 59 Receptor Antagonists 59 Kinase Inhibitor 59 Septic Shock 59 Follicular Lymphoma 59 Relapsing Multiple Sclerosis 59 Renal Function 59 Randomized Double Blind 58 tipranavir 58 tigecycline 58 Valsartan 58 Taxotere chemotherapy 58 gemcitabine Gemzar 58 Vaxfectin TM 58 Severe Asthma 58 Pafuramidine 58 Tuberculosis Vaccine 58 Malignant Melanoma 58 Lupus Drug 58 Present Preclinical Data 58 Randomized Clinical Trial 58 Breast Cancers 58 Platelet Inhibition 58 Rotavirus Vaccine 58 gefitinib Iressa 58 Multicenter Trial 58 Antiplatelet Therapy 58 Gefitinib 58 DOXIL 58 Adalimumab 58 Drug Resistant 58 Corticosteroid 58 Bosentan 58 Demonstrates Potent 58 standard chemotherapy regimen 58 Refractory Hodgkin Lymphoma 58 Inflammatory Markers 58 trastuzumab Herceptin R 58 Taxotere docetaxel 58 Cell Lung Cancer 58 FASLODEX 58 Treated Patients 58 Treatment Naive HIV 58 Vidaza azacitidine 58 sunitinib Sutent 58 sunitinib malate 58 Genotypes 58 metastatic neuroendocrine tumors 58 RE MODEL 58 abacavir Ziagen 58 RNAi Therapeutic 58 Antiplatelet 58 Therapeutic Vaccines 58 Cetuximab Erbitux 58 Phase IIb Trial 58 Potentially Fatal 58 Protein Expression 58 Advanced Solid Tumors 58 Replacement Therapy 58 bortezomib Velcade 58 Factor Receptor 58 Relapsing Remitting Multiple Sclerosis 58 Cisplatin 58 Inflammatory Arthritis 58 receptor tyrosine kinase inhibitor 58 Innate Immune 58 Pralatrexate 58 Invasive Fungal Infections 58 Hormone Receptor Positive 58 relapsing multiple sclerosis 58 Plaque Psoriasis 58 Aptamer 58 Anastrozole 58 Pharmacokinetics PK 58 Randomised 58 posaconazole 58 Chronic Myeloid Leukemia 58 Heart Failure Patients 58 Receives Marketing Authorization 58 trastuzumab Herceptin 58 Peginterferon Alfa 2a 58 Liver Fibrosis 58 Potent Anti 58 5 fluorouracil leucovorin 58 Chemotherapy Improves 58 Drug Shows Promise 58 Antiviral Drugs 58 Antiviral Therapy 58 Thromboembolism 58 Isavuconazole 58 Randomized Controlled Trial 58 Fungal Infections 58 Lung Injury 58 Bicalutamide 58 Helicobacter pylori eradication 58 atrasentan 58 Demonstrates Positive 58 Moxifloxacin 58 Randomized Double Blind Placebo 58 Sustained Release 58 Insulin Therapy 58 Sentinel Lymph Node Biopsy 58 Tigecycline 58 Neoplasms 58 Nucleoside 58 Controlled Study 58 FOLFOX6 58 Tumor Necrosis Factor 58 Tocilizumab 58 CLL8 58 Romiplostim 58 Lung Cancer Survival 58 PEG IFN 58 Anticancer Agent 58 Radiation Induced 58 Randomised Study 58 cyclosporin 58 Significantly Improved 58 Interferon alfa 58 Alemtuzumab 58 Osteoporosis Treatment 58 MyVax R 58 Node Positive 58 Ozarelix 58 Abciximab 58 Symptom Relief 58 Kidney Function 58 Adefovir 58 Completes Patient Enrollment 58 Malaria Vaccine 58 Combination REOLYSIN R 58 Clinical Outcomes 58 Combo Therapy 58 Autologous 58 Dual Antiplatelet Therapy 58 Peginterferon Alfa 2b 58 Pazopanib 58 Bisphosphonate 58 Study Demonstrates 58 Salmeterol 58 Campath alemtuzumab 58 Decitabine 58 Liver Metastases 58 Natalizumab 58 invasive candidiasis 58 Dose Escalation 58 Data Suggest 58 Shown Effective 58 Ulcerative Colitis 58 Ovarian Cancer Patients 58 Initiates Clinical 58 Myocardial Ischemia 58 Epoetin Alfa 58 Kidney Transplant Patients 58 Uric Acid 58 Anticoagulant 58 Lymph Node 58 Zoledronic Acid 58 Stem Cell Transplants 58 antiangiogenic agents 57 Prostate Cancer Vaccine 57 Ischemic Stroke 57 Gene Mutation 57 pertuzumab 57 Boceprevir 57 Venous Thrombosis 57 evaluating tivozanib 57 palifermin 57 stage IIIB 57 Contrast Agents 57 Study Showed 57 Atypical Hemolytic Uremic Syndrome 57 Tumor Response 57 Mycophenolate Mofetil 57 Myeloma Patients 57 Randomized Phase II 57 PKC# 57 Lung Cancer Trial 57 dasatinib Sprycel 57 Overactive Bladder 57 Prostate Cancer Patients 57 Inhibits 57 Hematologic 57 Doxil ® 57 Angiolix 57 Mouse Model 57 Prostate Cancers 57 Paclitaxel Carboplatin 57 PROSTASCINT R 57 Insulin Resistance 57 Diabetic Patients 57 Treatment Resistant 57 Subcutaneous 57 Osteoporosis Drugs 57 Mutational 57 Mucosal 57 Hematological Cancers 57 Cancer Incidence Mortality 57 Temsirolimus 57 Aortic Stenosis 57 Metastases 57 Psoriasis Drug 57 neoadjuvant 57 Randomized Evaluation 57 Novel Inhibitor 57 Initiates Phase III 57 Cancer Vaccines 57 Retroviral 57 mapatumumab 57 INTELENCE 57 Palifosfamide 57 Successfully Completes Phase 57 monoclonal anti 57 Castration Resistant Prostate Cancer 57 Etoposide 57 Anti Angiogenesis 57 viral kinetics 57 Immune Responses 57 Potent Antiviral Activity 57 eflornithine 57 Anticancer Drugs 57 ISTODAX ® 57 Aggressive Prostate Cancer 57 Alinia 57 II Clinical Trial 57 Naive Patients 57 NDA Submission 57 Watchful Waiting 57 Enzastaurin 57 Antiretroviral Therapy 57 Hepatic Encephalopathy 57 antitumor effect 57 Cancer Treatments 57 Mitoxantrone 57 Schizophrenia Treatment 57 alkylating agent 57 DNA Methylation 57 Demonstrates Sustained 57 Hematopoietic 57 Darbepoetin Alfa 57 Dose Ranging Study 57 Therapeutic Potential 57 ON #.Na 57 Allergic Rhinitis 57 Drug Eluting 57 Antibacterials 57 Novel Mechanism 57 Observational Study 57 adjuvant 57 Phase 2b Trial 57 Leucovorin 57 Suicidality 57 Myelodysplastic Syndrome MDS 57 Hormone Therapy 57 Advanced Pancreatic Cancer 57 Metastatic Breast Cancer 57 cetuximab Erbitux ® 57 ara C 57 Multiple Myeloma Patients 57 Novel Small Molecule 57 Vertebral Fracture 57 Left Ventricular Dysfunction 57 Restenosis 57 Receives Positive Opinion 57 Predict Response 57 Mutagenesis 57 Novel Method 57 p# biomarker 57 Renal Tumors 57 Stem Cell Treatment 57 Skin Lesions 57 Intravitreal 57 fluorouracil 57 Phase III Trials 57 Efficacious 57 Proves Effective 57 Fludara 57 Systematic Review 57 Pharmacodynamics 57 Elderly Patients 57 boosted protease inhibitor 57 Pegylated Liposomal Doxorubicin 57 Enlarged Prostate 57 Hepatocellular 57 estramustine 57 Inactivation 57 phase IIIb 57 Gastrointestinal Stromal Tumors 57 Endometrial Cancer 57 dual endothelin receptor antagonist 57 cediranib 57 Tumor Progression 57 Novel Antibiotic 57 Ezetimibe 57 YONDELIS R 57 GnRH agonists 57 BRAF inhibitor 57 STRIDE PD 57 First Patient Dosed 57 Treatment Naïve 57 Transcription Factor 57 Randomized Phase 57 Fabry Disease 57 liposomal doxorubicin 57 pegylated interferon alfa 2b 57 sipuleucel T 57 chemoradiotherapy 57 HCV Protease Inhibitor 57 Prognostic Factors 57 5 FU leucovorin 57 Cancer Therapies 57 Clinical Trial Evaluating 57 Zarnestra 57 antiangiogenic therapy 57 Erectile Dysfunction Drug 57 HCV SPRINT 57 Photodynamic Therapy 57 Androgen Deprivation Therapy 57 Genes Involved 57 prostate cancer mCRPC 57 Everolimus 57 Cyclooxygenase 2 57 Stent Thrombosis 57 IL# PE#QQR 57 Initiates Enrollment 57 Bazedoxifene 57 Antigen Specific 57 R lenalidomide 57 Myocet 57 Effectively Treats 57 Interferon Gamma 57 Valortim R 57 Tyrosine Kinase Inhibitors 57 Clinical Evaluation 57 canakinumab 57 Selective Inhibitor 57 Oritavancin 57 Liver Failure 57 Noxafil 57 Camptosar ® 57 Chronic Lymphocytic Leukemia CLL 57 Expanded Indication 57 raltegravir 57 Patient Outcomes 57 vorinostat 57 Protease 57 Cinacalcet 57 Significantly Improves 57 Seasonal Influenza Vaccine 57 Xanafide 57 Tezampanel 56 Cancer Vaccine 56 Proven Effective 56 Ovarian Cancers 56 Conjugate 56 Hospital Acquired Pneumonia 56 Ambrisentan 56 trastuzumab Herceptin ® 56 MabCampath 56 Microbicide 56 Chemotherapy Induced Anemia 56 etanercept Enbrel 56 Relapsed Multiple Myeloma 56 Trial Evaluating 56 Oral Anticoagulant 56 Non Responders 56 Monoclonal 56 Investigational Treatment 56 Influenza Vaccine 56 Shows Statistically Significant 56 Pharmacogenomic 56 PEGylated anti 56 Rituximab 56 Fixed Dose 56 HDAC Inhibitor 56 Corticosteroids 56 neratinib 56 Cloretazine ® 56 Reduced Incidence 56 fallopian tube carcinoma 56 Pivotal Phase II 56 Osteoarthritis Pain 56 Autoimmune Diseases 56 Inflammatory Pain 56 Diabetic Foot Ulcers 56 BiTE Antibody 56 Contrast Enhanced 56 Glioma 56 Myelofibrosis 56 Lupus Nephritis 56 Liver Cancer 56 AnaSpec Introduces 56 EGFR antibodies 56 Endothelial Cells 56 Treatment Regimens 56 Clinical Relevance 56 Antipsychotic 56 Peripheral Blood 56 Peginterferon alfa 2b 56 fludarabine 56 Interferon 56 Prostate Cancer Diagnosis 56 Stomach Cancer 56 Randomized Clinical Trials 56 FOLPI 56 Contrast Agent 56 icatibant 56 Xeloda ® 56 Reductase 56 oral prodrug 56 mertansine 56 BEACOPP 56 Exemestane 56 BAL# [002] 56 Experimental Vaccine 56 ABVD 56 Endovascular Treatment 56 Attack Trial ALLHAT 56 Treatment Experienced 56 Clopidogrel 56 Peripheral Arterial 56 Enoxaparin 56 Thiovir 56 Bevacizumab Avastin 56 galiximab 56 Smooth Muscle 56 Breast Density 56 Proton Pump Inhibitors 56 Myocardial Perfusion Imaging 56 Chronic Sinusitis 56 TORISEL 56 Nebulized 56 milatuzumab 56 bendamustine 56 targeting CD# 56 Sustained Virologic Response 56 Percutaneous Tibial Nerve Stimulation 56 imatinib Gleevec 56 Pivotal Trials 56 Cholesterol Lowering Drug 56 Antifungals 56 Phase III Clinical Trials 56 Insulin Glargine 56 gastrointestinal stromal tumors GIST 56 adjuvant radiation 56 Taxanes 56 sorafenib tablets 56 Respiratory Virus 56 Targeted Therapies 56 Amrubicin 56 Orphan Status 56 #F FDG PET CT 56 Topotecan 56 cetuximab Erbitux R 56 Pivotal Phase 56 G#DT 56 Regenerative Cells 56 KRAS mutation 56 F FDG PET 56 Personalized Immunotherapy 56 Molecular Basis 56 tocilizumab 56 meropenem 56 Pharmacodynamic 56 Polymorphisms 56 gemcitabine carboplatin 56 Gout Drug 56 Cancer Cells 56 Retreatment 56 Pivotal Phase III 56 Romidepsin 56 protease inhibitor PI 56 Renin Inhibitor 56 Phase Ib II 56 Systolic Blood Pressure 56 Trastuzumab DM1 56 alfa 2a 56 Vitaxin 56 Patient Recruitment 56 Toxicogenomics 56 prostate cancer CRPC 56 intravesical instillation 56 humanised monoclonal antibody 56 HuMax CD4 56 Develop Novel 56 Budesonide 56 Elotuzumab 56 Multicenter 56 Teriparatide 56 betamethasone dipropionate 56 PANVAC VF 56 Omacetaxine 56 Hepatitis C Patients 56 ST Segment Elevation 56 Attenuates 56 Newly Diagnosed 56 neoadjuvant treatment 56 recurrent metastatic 56 cidofovir 56 Nicotine Vaccine 56 docetaxel Taxotere 56 OMP #M# 56 Ziprasidone 56 oxaliplatin Eloxatin 56 EGFR HER2 56 Minimally Invasive Treatment 56 riociguat 56 Androgen Receptor 56 Oral Insulin 56 Randomized Phase III 56 Somatostatin 56 Autoimmune Disease 56 sunitinib Sutent ® 56 Receptor Signaling 56 5FU 56 antiviral efficacy 56 Paclitaxel 56 B Cell Lymphoma 56 Non inferiority 56 Transdermal Patch 56 Talabostat 56 Anemia Drug 56 Montelukast 56 Psoriasis Patients 56 Vaccine Protects Against 56 Randomized Trials 56 Mimetics 56 Treatment Naive 56 Bacteremia 56 Long Term Outcomes 56 Inflammatory Diseases 56 Significantly Reduces 56 CYT# potent vascular disrupting 56 Docetaxel 56 Genomic Grade 56 Aromatase Inhibitors 56 panitumumab Vectibix 56 Cloretazine 56 raloxifene Evista 56 Therapy Reduces 56 Rheumatoid Arthritis 56 Obese Patients 56 TKI therapy 56 Prophylactic Treatment 56 Hepatitis C Genotype 56 Vidaza ® 56 Phase IIA 56 temsirolimus 56 PEGylated interferon 56 Traficet EN 56 HuMax EGFr 56 Lipid Lowering 56 Demonstrates Potential 56 Study Shows Significant 56 Protein Interactions 56 Arthritis Drug 56 IIa Clinical Trial 56 Breast Cancer Risk 56 Oxidative Stress 56 FUSILEV enhances 56 Cancer Biomarkers 56 Squamous 56 Detection Device 56 Pivotal Clinical Trial 56 Renal Artery 56 Golimumab 56 HGS ETR2 56 Bacterial Vaginosis 56 Relapsed Refractory Aggressive 56 Etanercept 56 Platinol ® cisplatin 56 Accelerated Partial Breast Irradiation 56 Copegus R 56 Initiates Clinical Trial 56 TO AVOID PREGNANCY WHILE 56 Proteasome 56 Chemotherapeutic 56 Modulates 56 C1 Inhibitor 56 Gene Silencing 56 Randomized Comparison 56 EBMT criteria 56 Pre Exposure Prophylaxis 56 KRAS status 56 PROSTVAC VF 56 FDA Approvals 56 Medullary Thyroid Cancer 56 pharmacodynamic parameters 56 Tyrosine Kinase 56 Placebo Controlled Study 56 lapatinib Tykerb 55 Afatinib 55 Myelodysplastic Syndrome 55 epoetin alpha 55 Total Knee Arthroplasty 55 Proxinium TM 55 Valopicitabine 55 Immunomedics Announces 55 Treatment Reduces 55 Celecoxib 55 Prognostic Value 55 Vaginal Gel 55 Aflibercept 55 Combination Clinical Trial 55 HCV Genotype 55 Saquinavir 55 Phase III Pivotal 55 BRIM2 55 Copegus ribavirin 55 Medoxomil 55 ORENCIA ® 55 Ovarian Cancer Screening 55 Oncolytic Reovirus 55 Treatment Outcome 55 Hepatocellular Carcinoma HCC 55 Fibrin Sealant 55 Hepatitis B Vaccine 55 metastatic castration resistant 55 MGCD# [001] 55 ixabepilone 55 MAGE A3 ASCI 55 Rituxan rituximab 55 Molecular Weight Heparin 55 EGFR TKI 55 sunitinib 55 Carotid Endarterectomy 55 decitabine 55 Carboplatin Paclitaxel 55 Ribavirin 55 Chronic Pelvic Pain 55 Topical Treatment 55 Unstable Angina 55 Abiraterone 55 Patency 55 XELOX